BioMarin Pharma (BMRN) Announces Positive Interim Phase 1/2 Data on BMN 270 in Hemophilia A at JPMorgan Conference
Tweet Send to a Friend
Over the weekend BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its positive interim results of an open-label ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
